<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>HIV/AIDS News &#38; Information &#187; cancer</title>
	<atom:link href="http://www.hiv-infected.com/category/cancer/feed" rel="self" type="application/rss+xml" />
	<link>http://www.hiv-infected.com</link>
	<description></description>
	<lastBuildDate>Sat, 17 Jul 2010 01:23:38 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>American Society of Clinical Oncology: Combination Immunotherapy for Advanced NHL</title>
		<link>http://www.hiv-infected.com/2010/07/american-society-of-clinical-oncology-combination-immunotherapy-for-advanced-nhl.html</link>
		<comments>http://www.hiv-infected.com/2010/07/american-society-of-clinical-oncology-combination-immunotherapy-for-advanced-nhl.html#comments</comments>
		<pubDate>Mon, 05 Jul 2010 03:16:27 +0000</pubDate>
		<dc:creator>Steve</dc:creator>
				<category><![CDATA[cancer]]></category>
		<category><![CDATA[Clinical Oncology]]></category>

		<guid isPermaLink="false">http://www.hiv-infected.com/?p=1781</guid>
		<description><![CDATA[
Speaker: Deborah Hurst, MD, Senior Director of Clinical Development, Chiron Corporation, Emeryville, California.
Low-dose interleukin-2 (IL-2) (Proleukin, Chiron), when administered in combination with rituximab (Rituxan, Genen-tech/IDEC) produces positive clinical responses in patients with advanced non-Hodgkin&#8217;s lymphoma (NHL), augmenting the antitumor activity of rituximab via expansion and activation of natural killer (NK) cells.
To establish the maximum tolerated [...]]]></description>
		<wfw:commentRss>http://www.hiv-infected.com/2010/07/american-society-of-clinical-oncology-combination-immunotherapy-for-advanced-nhl.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>American Society of Clinical Oncology: 90Yttrium-Labeled Glass Microspheres for Unresectable HCC</title>
		<link>http://www.hiv-infected.com/2010/07/american-society-of-clinical-oncology-90yttrium-labeled-glass-microspheres-for-unresectable-hcc.html</link>
		<comments>http://www.hiv-infected.com/2010/07/american-society-of-clinical-oncology-90yttrium-labeled-glass-microspheres-for-unresectable-hcc.html#comments</comments>
		<pubDate>Sun, 04 Jul 2010 03:16:26 +0000</pubDate>
		<dc:creator>Steve</dc:creator>
				<category><![CDATA[cancer]]></category>
		<category><![CDATA[Clinical Oncology]]></category>

		<guid isPermaLink="false">http://www.hiv-infected.com/?p=1780</guid>
		<description><![CDATA[Speaker: Brian I. Carr, MD, Professor of Medicine, Director of the Liver Tumor Service, and Head of the Starzl Transplant Institute, University of Pittsburgh, Pittsburgh, Pennsylvania.
Glass beads that release highly targeted p-rays from 90yttrium (Therasphere, MDS Nordion) represent an effective and relatively non-toxic treatment option for patients with unresectable and untransplantable advanced-stage hepatocel-lular carcinoma (HCC) [...]]]></description>
		<wfw:commentRss>http://www.hiv-infected.com/2010/07/american-society-of-clinical-oncology-90yttrium-labeled-glass-microspheres-for-unresectable-hcc.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>American Society of Clinical Oncology: Oral EGF Receptor Inhibitor for Advanced, Refractory NSCLC</title>
		<link>http://www.hiv-infected.com/2010/07/american-society-of-clinical-oncology-oral-egf-receptor-inhibitor-for-advanced-refractory-nsclc.html</link>
		<comments>http://www.hiv-infected.com/2010/07/american-society-of-clinical-oncology-oral-egf-receptor-inhibitor-for-advanced-refractory-nsclc.html#comments</comments>
		<pubDate>Sat, 03 Jul 2010 03:16:25 +0000</pubDate>
		<dc:creator>Steve</dc:creator>
				<category><![CDATA[cancer]]></category>
		<category><![CDATA[Clinical Oncology]]></category>

		<guid isPermaLink="false">http://www.hiv-infected.com/?p=1779</guid>
		<description><![CDATA[Speaker: Ronald B. Natale, MD, Acting Medical Director, Cedars-Sinai Comprehensive Cancer Center, Beverly Hills, California.
Targeted therapy with the investigational oral epidermal growth factor (EGF) receptor inhibitor ZD1839 (Iressa, Astra Zeneca) was able to shrink tumors in some patients with advanced non-small cell lung cancer (NSCLC) who were resistant to treatment with more than two prior [...]]]></description>
		<wfw:commentRss>http://www.hiv-infected.com/2010/07/american-society-of-clinical-oncology-oral-egf-receptor-inhibitor-for-advanced-refractory-nsclc.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>American Society of Clinical Oncology</title>
		<link>http://www.hiv-infected.com/2010/07/american-society-of-clinical-oncology.html</link>
		<comments>http://www.hiv-infected.com/2010/07/american-society-of-clinical-oncology.html#comments</comments>
		<pubDate>Fri, 02 Jul 2010 03:29:48 +0000</pubDate>
		<dc:creator>Steve</dc:creator>
				<category><![CDATA[cancer]]></category>
		<category><![CDATA[Clinical Oncology]]></category>

		<guid isPermaLink="false">http://www.hiv-infected.com/?p=1778</guid>
		<description><![CDATA[
Tamoxifen as Standard Adjuvant Hormonal Treatment
Speaker: Eric P. Winer, MD, Director of the Breast Oncology Center, Dana Farber Cancer Institute, and Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts.
Assessing the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor positive (HR+) breast cancer, an American Society of Clinical Oncology panel stated [...]]]></description>
		<wfw:commentRss>http://www.hiv-infected.com/2010/07/american-society-of-clinical-oncology.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Innovative Cancer Therapy for Tomorrow: Melphalan, Arsenic Trioxide, and Ascorbic Acid for Multiple Myeloma</title>
		<link>http://www.hiv-infected.com/2010/03/innovative-cancer-therapy-for-tomorrow-melphalan-arsenic-trioxide-and-ascorbic-acid-for-multiple-myeloma.html</link>
		<comments>http://www.hiv-infected.com/2010/03/innovative-cancer-therapy-for-tomorrow-melphalan-arsenic-trioxide-and-ascorbic-acid-for-multiple-myeloma.html#comments</comments>
		<pubDate>Mon, 22 Mar 2010 11:17:40 +0000</pubDate>
		<dc:creator>Steve</dc:creator>
				<category><![CDATA[cancer]]></category>
		<category><![CDATA[Foundation Symposium]]></category>

		<guid isPermaLink="false">http://www.hiv-infected.com/?p=1428</guid>
		<description><![CDATA[
Presenter: James Berenson, MD, Medical and Scientific Director, Institute for Myeloma and Bone Cancer Research, West Hollywood, California
Multiple myeloma (MM) is an incurable B-cell malignancy, and resistance develops in nearly all patients. Most patients develop renal insufficiency, which is associated with poor survival.
Arsenic trioxide (Trisenox, Cephalon) is an active anti-myeloma agent. Ascorbic acid enhances the [...]]]></description>
		<wfw:commentRss>http://www.hiv-infected.com/2010/03/innovative-cancer-therapy-for-tomorrow-melphalan-arsenic-trioxide-and-ascorbic-acid-for-multiple-myeloma.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
